

# **4<sup>th</sup> International Conference on Cardiomyopathy in Children**

### May 18-19, 2017 Bethesda North Marriott Hotel and Conference Center, MD

### **Thursday, May 18, 2017**

Continental Breakfast
Opening Remarks: Steven E. Lipshultz, MD and Lisa Yue, CCF founding executive director
Session 1: New Heart Failure Targets
<ul> <li>Session Leaders: Daphne Hsu, MD and Paul Kantor, MBBCh, DCH</li> <li>Mitochondrial remodeling         <ul> <li>Dan Bernstein, MD (Mayo Clinic)</li> </ul> </li> <li>Neurohormonal targets: Entresto, Serelaxin, tolvaptan)         <ul> <li>Robert Shaddy, MD (CHOP)</li> </ul> </li> <li>Non-cardiac targets to treat heart failure in children: exercise, nutrition, anemia.         <ul> <li>Beth Kaufman, MD (Stanford)</li> </ul> </li> <li>Panel Discussion</li> </ul>
Session 2: Optimizing donor quality for pediatric heart transplantation
<ul> <li>Session Leaders: Steven Webber, MD and Michael Burch, MB ChB, MD</li> <li>Clinical and echocardiographic risk assessment of donor quality         Anne Dipchand, MD (Hospital for Sick Children)</li> <li>Serum biomarkers of primary graft failure         Charles Canter, MD (Washington University in St. Louis)</li> <li>Pharmacologic resuscitation of donors – old tricks, new twists         Steve Webber, MBChB, MRCP (Vanderbilt University)</li> <li>Continuous donor perfusion for heart preservation         Richard Kirk, MA MB BChir (Newcastle Upon Tyne)</li> <li>Panel Discussion</li> </ul>
Break
Session 3: Current controversies in diagnosis and management
<ul> <li>Session Leader: Steve Colan, MD</li> <li>Management and indications for transplant in restrictive cardiomyopathy         Elizabeth Blume (Boston Children's)</li> <li>Evidence concerning efficacy of exercise restriction in hypertrophic cardiomyopathy         Mark Friedberg (RAND Corporation)</li> <li>Indications for primary prevention ICD implantation in children with hypertrophic cardiomyopathy</li> </ul>

Dominic Abrams. MD (Boston Children's)

**Panel Discussion** 

11:50 am - 12:50 pm

# Session 4: New cutting-edge topics that including studies/approaches leading to future pathophysiologic understanding of the diseases

Session Leader: Jeffrey Towbin, MD

- Scientific basis of overlapping syndromes: cardiomyopathy and arrhythmias.

   Inffront Touchin, MD (University of Tonnessee)
  - Jeffrey Towbin, MD (University of Tennessee)
- Scientific basis of overlapping syndromes: cardiomyopathy and congenital heart disease.

Weinian Shou, PhD (Indiana University)

- New insights into hemato-onco-cardiology.
  - -Jean Ballweg, MD (University of Tennessee)
- Cardio-renal interactions and diseases.
- Genes and proteins: the mechanisms of cardiomyopathies.

Jeffrey Saffitz, MD, PhD (Harvard)

12:50 pm – 1:50 pm 1:50 pm – 3:10 pm

#### Lunch

#### Session 5: State-of-the-art current knowledge

Session Leader: Melanie Everitt, MD and Robert Weintraub, MB.BS

 Age and Gender Differences in Response to Heart Failure Medications in Children: Evidence for What Works and Impact for Future Trials

Carmen Sucharov, PhD (University of Colorado)

Shelley Miyamoto, MD (University of Colorado)

 Risk Stratification in Pediatric Hypertrophic Cardiomyopathy: Insights for Bridging the Evidence Gap?

Shaji Menon, MD (Primary Children's Hospital)

 Implantable Cardiac Defibrillators in Pediatric Hypertrophic Cardiomyopathy: Programming to Avoid Inappropriate Shocks—Should There be a Different Threshold for Primary vs. Secondary Prevention

Anne Dubin, MD (Stanford)

• ICDs and Biventricular Pacing in Pediatric Dilated Cardiomyopathy: Preventing Death and Delaying Heart Transplant

Charles Berul, MD (Children's National)

- Exercise Training for Children with Cardiomyopathy
   Philip Thrush, MD (Lurie Children's Hospital)
- Panel Discussion

3:10 pm - 3:20 pm

#### **Break**

3:20 pm - 5:25 pm

#### **Young Investigator Abstracts**

Moderator: James Wilkinson, MD

5:30 pm - 8:30 pm

Dinner

### Friday, May 19, 2017

7:30 am

#### **Continental Breakfast**

8:00am - 8:50 am

#### Session 6: Update on ventricular assist devices and PumpKIN trial

Session Leader: Charles Canter, MD

Pumpkin status

William Mahle, MD (Emory)

 Contemporary trends in VAD us in pediatric dilated cardiomyopathy: insights from PEDIMACs

David Rosenthal, MD (Stanford)

VADs as a tool for myocardial recovery

Christina VanderPluym (Boston)

• Utilization of VADs in restrictive and hypertrophic cardiomyopathy

Angela Lorts, MD (Cincinnati Children's)

8:50 am - 10:00 am

#### Session 7: Gene-directed therapies

Session Leader: Wendy Chung, MD

• Novel gene discoveries in pediatric cardiomyopathy:

Stephanie Ware, MD, PhD (Indiana University)

Teresa Lee, MD (Columbia)

• Prevention of cardiomyopathy in genetically at-risk individuals

Carolyn Ho (Brigham and Women's Hospital)

Molecular treatment of genetic cardiomyopathies

Christine Seidman, MD (Harvard)

Panel Discussion

10:00 am - 10:10 am

#### **Break**

10:10 am - 11:00 am

## Session 8: Development of new translationally-derived diagnostic markers and new targeted therapies

Session Leader: John Lynn Jefferies, MD

• The use of microRNAs in the diagnosis of heart failure

Jeffrey Robbins, PhD (CCHMC)

Derived biomarkers panelists:

Michael Taylor, MD (Cincinnati Children's)

• Targeting protein kinase C: A novel paradigm for heart failure therapy

John Lynn Jefferies, MD (Cincinnati Children's)

New targeted therapies panelists:

Steven Colan, MD (Boston Children's)

11:00 am - 11:45 am

### Session 9: Pediatric Cardiomyopathy Registry biomarker and genetics studies

Session Speaker: James D. Wilkinson, MD, MPH

11:45 am - 12:45 pm

#### Lunch

12:45 pm - 1:55 pm

# Session 10: Designing reliable clinical microsystems centered around the needs of cardiomyopathy children and their families

(Four 10-minute presentations and 30-minute panel discussion = 70 minutes)

Session Leader: Paul Barach, MD

Presenters:

 Helen Haskell, MA, IHI Board Member and President (Mothers Against Medical Errors)

- Julie Johnson, PhD, (Feinberg School of Medicine, Northwestern University)
- Lawrence C. Kleinman, MD, MPH, (Case Western)

Panel Discussion

1:55 pm - 3:00 pm

Conference Wrap Up: Steven E. Lipshultz, MD

3:00 pm

Conference Adjournment